{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T16:12:40Z","timestamp":1788797560518,"version":"build-2803163510"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"52","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>\n                      The present study was performed to investigate whether the markedly 2-deoxy-2-(fluorine-18) fluoro-D-glucose (\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG) uptake in the bone marrow (BM) is a presentation of malignant infiltration (MI).\n                    <\/jats:p>\n                    <jats:p>\n                      Super bone marrow uptake (super BMU) was used to name the markedly\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG uptake on BM, which was similar to or higher than that of the brain. From April 2008 to December 2015, 31 patients with such presentation were retrospectively reviewed. The\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG uptake was semiquantified using SUVmax and BM to cerebellum (BM\/C) ratio. The origin of super BMU was diagnosed by pathology. Some blood parameters, as well as fever, were also collected and analyzed. For comparison, 106 patients with mildly and moderately uptake in BM and 20 healthy subjects were selected as the control group.\n                    <\/jats:p>\n                    <jats:p>\n                      Bone marrow MI was diagnosed in 93.5% (29\/31) patients with super BMU, which mostly originated from acute leukemia and highly aggressive lymphoma. The super BMU group had markedly higher\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG uptake in the BM than those of mildly and moderately uptake, and the control subjects (all\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a=\u200a0.000) and the BM\/C ratio reached a high of 1.24\u200a\u00b1\u200a0.36. The incidence of bone marrow MI in the super BMU group was markedly higher than that of mildly and moderately uptake (93.5% vs 36.8%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a=\u200a0.000). Based on the receiver operating characteristic analysis, when cut-off values of BM\/C and SUVmax were set at 0.835 and 6.560, the diagnostic specificity for bone marrow MI reached the high levels of 91.4% and 95.7%, respectively. In 15 patients with bone marrow MI, the extra-BM malignant lesions were simultaneously detected by\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT. The liver and the nasal cavity involvements were only found in the patients with lymphoma, but not in those with leukemia. A decrease of leukocyte, hemoglobin, and platelet counts was noted in 48.4%, 86.2%, and 51.5% of patients with bone marrow MI, respectively.\n                    <\/jats:p>\n                    <jats:p>The present study revealed that super BMU was a highly potent indicator for the bone marrow MI.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000005579","type":"journal-article","created":{"date-parts":[[2016,12,29]],"date-time":"2016-12-29T14:06:09Z","timestamp":1483020369000},"page":"e5579","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":18,"title":["18F-FDG super bone marrow uptake"],"prefix":"10.1097","volume":"95","author":[{"given":"Mohammed Shah","family":"Alam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilan","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Yan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu-Bing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan-Shi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Jiang","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Lan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Sheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20260907","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.2967\/jnumed.114.141424","article-title":"Molecular imaging to plan radiotherapy and evaluate its efficacy","volume":"56","author":"Jeraj","year":"2015","journal-title":"J Nucl Med"},{"key":"R2-10-20260907","doi-asserted-by":"crossref","first-page":"995","DOI":"10.2967\/jnumed.115.155580","article-title":"Diagnostic performance of 18F-FDG PET and PET\/CT for the detection of recurrent esophageal cancer after treatment with curative intent: a systematic review and meta-analysis","volume":"56","author":"Goense","year":"2015","journal-title":"J Nucl Med"},{"key":"R3-10-20260907","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.radonc.2015.03.014","article-title":"PET\/CT imaging for target volume delineation in curative intent radiotherapy of non-small cell lung cancer: IAEA consensus report 2014","volume":"116","author":"Konert","year":"2015","journal-title":"Radiother Oncol"},{"key":"R4-10-20260907","doi-asserted-by":"crossref","first-page":"523","DOI":"10.2967\/jnumed.114.150946","article-title":"Improving patient selection for 18F-FDG PET scanning in the staging of gastric cancer","volume":"56","author":"Kaneko","year":"2015","journal-title":"J Nucl Med"},{"key":"R5-10-20260907","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s00259-014-2973-6","article-title":"FDG PET\/CT imaging as a biomarker in lymphoma","volume":"42","author":"Meignan","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R6-10-20260907","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.1097\/RLU.0000000000000640","article-title":"Analysis of the roles of glucose transporter 1 and hexokinase 2 in the metabolism of glucose by extrahepatic bile duct cancer cells","volume":"40","author":"Yoon","year":"2015","journal-title":"Clin Nucl Med"},{"key":"R7-10-20260907","doi-asserted-by":"crossref","first-page":"7583","DOI":"10.1158\/0008-5472.CAN-14-1235","article-title":"Oncogene pathway activation in mammary tumors dictates FDG-PET uptake","volume":"74","author":"Alvarez","year":"2014","journal-title":"Cancer Res"},{"key":"R8-10-20260907","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000358163","article-title":"Correlation between expression of biological markers and [F]fluorodeoxyglucose uptake in endometrial cancer","volume":"37","author":"Jo","year":"2014","journal-title":"Oncol Res Treat"},{"key":"R9-10-20260907","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2967\/jnumed.113.121327","article-title":"Propranolol inhibits glucose metabolism and 18F-FDG uptake of breast cancer through posttranscriptional downregulation of hexokinase-2","volume":"55","author":"Kang","year":"2014","journal-title":"J Nucl Med"},{"key":"R10-10-20260907","doi-asserted-by":"crossref","first-page":"e244","DOI":"10.1097\/RLU.0000000000001163","article-title":"FLT PET\/CT is better than FDG PET\/CT in differentiating benign from malignant pancreatobiliary lesions","volume":"41","author":"Vineeth Kumar","year":"2016","journal-title":"Clin Nucl Med"},{"key":"R11-10-20260907","first-page":"366","article-title":"False-positive uptake on 2-[18F]-fluoro-2-deoxy-D-glucose (FDG) positron-emission tomography\/computed tomography (PET\/CT) in oncological imaging","volume":"66","author":"Culverwell","year":"2011","journal-title":"ClinRadiol"},{"key":"R12-10-20260907","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1007\/s11307-010-0459-x","article-title":"Clinical utility of FDG-PET and PET\/CT in non-malignant thoracic disorders","volume":"13","author":"Basu","year":"2011","journal-title":"Mol Imaging Biol"},{"key":"R13-10-20260907","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1186\/s40064-015-1339-2","article-title":"Increased bone marrow uptake of 18F-FDG in leukemia patients: preliminary findings","volume":"4","author":"Arimoto","year":"2015","journal-title":"Springerplus"},{"key":"R14-10-20260907","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/ejh.12483","article-title":"Diffusely increased bone marrow FDG uptake in recently untreated lymphoma: incidence and relevance","volume":"95","author":"Adams","year":"2015","journal-title":"Eur J Haematol"},{"key":"R15-10-20260907","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.2967\/jnumed.113.134486","article-title":"Combined PET and biopsy evidence of marrow involvement improves prognostic prediction in diffuse large B-cell lymphoma","volume":"55","author":"Cerci","year":"2014","journal-title":"J Nucl Med"},{"key":"R16-10-20260907","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1007\/s00259-015-3117-3","article-title":"FDG-PET\/CT findings in systemic mastocytosis: a French multicentre study","volume":"42","author":"Djelbani-Ahmed","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R17-10-20260907","first-page":"2047","article-title":"(18)F-FDG PET\/CT in patients with adult-onset Still's disease","volume":"34","author":"Dong","year":"2015","journal-title":"ClinRheumatol"},{"key":"R18-10-20260907","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1097\/RLU.0b013e31829b1f26","article-title":"Increased FDG uptake of the bone marrow mimicking malignancy in a patient of eosinophilia secondary to Sparganum mansoni infection","volume":"39","author":"Dong","year":"2014","journal-title":"Clin Nucl Med"},{"key":"R19-10-20260907","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/01.rlu.0000115654.90324.02","article-title":"Diffuse bone marrow uptake on whole-body F-18 fluorodeoxyglucose positron emission tomography in a patient taking recombinant erythropoietin","volume":"29","author":"Blodgett","year":"2004","journal-title":"Clin Nucl Med"},{"key":"R20-10-20260907","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1200\/JCO.1998.16.1.173","article-title":"Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy","volume":"16","author":"Sugawara","year":"1998","journal-title":"J Clin Oncol"},{"key":"R21-10-20260907","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s12149-009-0286-9","article-title":"A bone marrow F-18 FDG uptake exceeding the liver uptake may indicate bone marrow hyperactivity","volume":"23","author":"Inoue","year":"2009","journal-title":"Ann Nucl Med"},{"key":"R22-10-20260907","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1007\/s00259-009-1183-0","article-title":"Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin's lymphoma: a reflection of disease infiltration or just inflammation?","volume":"36","author":"Salaun","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R23-10-20260907","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/RLU.0b013e318208f503","article-title":"Super-superscan on a bone scintigraphy","volume":"36","author":"Liu","year":"2011","journal-title":"Clin Nucl Med"},{"key":"R24-10-20260907","first-page":"291","article-title":"The \u201csuper\u201d bone scan","volume":"72","author":"Higginbotham","year":"1980","journal-title":"J Natl Med Assoc"},{"key":"R26-10-20260907","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/RLU.0b013e318053ed37","article-title":"Super scan in a patient with diffuse bone metastases from intracranial glioma","volume":"32","author":"Shinya","year":"2007","journal-title":"Clin Nucl Med"},{"key":"R27-10-20260907","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/RLU.0b013e318184b435","article-title":"Improved discrimination of benign and malignant lesions on FDG PET\/CT, using comparative activity ratios to brain, basal ganglia, or cerebellum","volume":"33","author":"Britz-Cunningham","year":"2008","journal-title":"Clin Nucl Med"},{"key":"R28-10-20260907","doi-asserted-by":"crossref","first-page":"e300","DOI":"10.1097\/RLU.0000000000000773","article-title":"(18)F-FDG dynamic PET\/CT in patients with multiple myeloma: patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate","volume":"40","author":"Sachpekidis","year":"2015","journal-title":"Clin Nucl Med"},{"key":"R29-10-20260907","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1097\/RLU.0b013e3181b81cbd","article-title":"High F-18 FDG uptake in bone marrow by cytokines secreting ectopic mucoepidermoid carcinoma","volume":"34","author":"Balink","year":"2009","journal-title":"Clin Nucl Med"},{"key":"R30-10-20260907","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1097\/RLU.0b013e318148b434","article-title":"Rhabdomyosarcoma with widespread bone marrow infiltration: beneficial management role of F-18 FDG PET","volume":"32","author":"Seshadri","year":"2007","journal-title":"Clin Nucl Med"},{"key":"R31-10-20260907","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/RLU.0b013e3182335f9b","article-title":"F-18 FDG PET\/CT for detecting bone and bone marrow involvement in sarcoidosis patients","volume":"37","author":"Mostard","year":"2012","journal-title":"Clin Nucl Med"},{"key":"R32-10-20260907","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0212-6982(04)72267-3","article-title":"Splenic and bone marrow increased 18F-FDG uptake in a PET scan performed following treatment with G-CSF\/granulocyte colony-stimulating factor","volume":"23","author":"Ruiz-Hern\u00e1ndez","year":"2004","journal-title":"Rev Esp Med Nucl"},{"key":"R33-10-20260907","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1097\/RLU.0000000000000491","article-title":"The alteration of 18F-FDG uptake in bone marrow after treatment with interleukin 11","volume":"39","author":"Yi","year":"2014","journal-title":"Clin Nucl Med"},{"key":"R34-10-20260907","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.2967\/jnumed.112.114710","article-title":"In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET\/CT provides better diagnostic performance and prognostic stratification than does biopsy","volume":"54","author":"Berthet","year":"2013","journal-title":"J Nucl Med"},{"key":"R35-10-20260907","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ejrad.2015.11.019","article-title":"Usefulness and pitfalls of F-18-FDG PET\/CT for diagnosing extramedullary acute leukemia","volume":"85","author":"Zhou","year":"2016","journal-title":"Eur J Radiol"},{"key":"R36-10-20260907","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1097\/RLU.0b013e3182485277","article-title":"Diffuse homogeneous bone marrow uptake of FDG in patients with acute lymphoblastic leukemia","volume":"38","author":"Su","year":"2013","journal-title":"Clin Nucl Med"},{"key":"R37-10-20260907","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00277-010-1129-4","article-title":"Primary bone marrow diffuse large B cell lymphoma: a case series and review","volume":"90","author":"Chang","year":"2011","journal-title":"Ann Hematol"},{"key":"R38-10-20260907","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s13139-012-0153-9","article-title":"Usefulness of (18)F-FDG PET\/CT for the evaluation of bone marrow involvement in patients with high-grade non-Hodgkin's lymphoma","volume":"46","author":"Lee","year":"2012","journal-title":"Nucl Med Mol Imaging"},{"key":"R39-10-20260907","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s00259-008-1021-9","article-title":"Bone marrow involvement in diffuse large B-cell lymphoma: correlation between FDG-PET uptake and type of cellular infiltrate","volume":"36","author":"Paone","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R40-10-20260907","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","article-title":"An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era","volume":"123","author":"Zhou","year":"2014","journal-title":"Blood"},{"key":"R41-10-20260907","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/1097-0142(197508)36:2<428::AID-CNCR2820360218>3.0.CO;2-H","article-title":"Nodular lymphoma: bone marrow and blood manifestations","volume":"36","author":"McKenna","year":"1975","journal-title":"Cancer"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00005792-201612300-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T16:04:05Z","timestamp":1788797045000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00005792-201612300-00010"}},"subtitle":["A highly potent indicator for the malignant infiltration"],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":40,"journal-issue":{"issue":"52","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000005579","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12]]}}}